Donald M. O’Rourke, MD, reviews the application of recent advances in personalized cancer immunology to the treatment of glioblastoma, including a pilot study currently underway at Penn Neurosciences to evaluate the safety and feasibility of engineered autologous T-cells with a chimeric antigen receptor (CAR T) in patients with EGFRvIII positive glioblastoma. In addition to reporting on study activity thus far, Dr. O’Rourke examines imaging challenges, safety and tolerability of the therapy, and the complexity of EGFR mutations, as recorded by Penn Center for Personalized Diagnostics.
Related Links:
Published
November 17, 2017
Created by
BROADCASTMED